Washington DC-Baltimore Area
Expertly trained and highly skilled computational biologist with a broad scientific background specializing in integrative study of multi-modal data for developing new cancer medicines such as patient stratification, indication prioritization, drug MOA characterization & differentiation, resistance/synergy mechanism deciphering, combination prediction and biomarker discovery. Extensive and deep R&D experience (20 years) in a multi-disciplinary setting, with proven track record of driving strategy & projects throughout drug pipeline from target identification to drug discovery to translational/precision medicine to late-stage clinical development and regulatory approval. CompBio lead for a variety of flagship/anchor assets spanning tumor-intrinsic and immuno-oncology therapies including IBRANCE, XTANDI and IMFINZI. Demonstrated management capabilities in building and supervising team of Ph.D. level Data Science/AI scientists with diverse talents and skillsets for advancing oncology portfolio. Strong publication & scientific record spanning clinical (clinical trials of all stages & Real-World Evidence), preclinical (multi-omics & functional genomics) and algorithm development, with established expertise in bi-directional translational research between bedside and benchside.